Sudarshan Pharma Industries Ltd · BSE:SUDARSHAN
Sudarshan Pharma Industries — IPO Roadshow (2019)
46 slides from Sudarshan Pharma Industries's IPO roadshow presentation, 2019
Slide 1: Sudarshan Pharma Industries Ltd Investor Presentation
Sudarshan Pharma Industries Ltd Investor Presentation
Slide 2: Table Of Contents
Table Of Contents Corporate Identity 03-19 Pharmaceutical Industry Overview 20-24 Road Ahead 25-34 Strong Financial Performance 35-40 IPO Issue Highlights 41-45 2
Slide 3: Corporate Identity
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Corporate Identity 3
Slide 4: About Us
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights About Us Core Business About Us In terms of geographies and therapeutic areas, SPIL has diversified business in the pharmaceutical and specialty chemicals industries. Specialty chemicals and intermediates Originally
Slide 5: Vision, Mission and Values
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Vision, Mission and Values Vision Values We aim to be among the top pharmaceutical companies in India by constantly evolving and bringing home innovative products in healthcare segment. Creation Integrity Safety Mis
Slide 6: Milestone
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Milestone Established our footprints in Gujarat, West Bengal, Generic formulations Chhattisgarh and Uttar Manufacturing of for institution supply, Pradesh Nutraceuticals Contract Over 5,000 medical NGO’s and wholesa
Slide 7: Geographical Reach
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Geographical Reach Exporting Countries Zambia Uttar Pradesh Tanzania West Africa Gujarat Bengal Chhattisgarh Australia Maharashtra Middle East UK CIS countries 5 Office States in Presence Plants R&D 70+ Field Force
Slide 8: Our Business Structure
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Our Business Structure SUDARSHAN PHARMA INDUSTRIES LTD (BUSINESS ACTIVITIES) INTERNATIONAL DOMESTIC MARKET MARKET SPECIALITY CHEMICAL DIRECT MARKETING PRODUCTS API/ FORMULATIONS/ OTHER PHARMA PRODUCTS IN-HOUSE SALES
Slide 9: Key Business Verticals
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Key Business Verticals Ethical marketing of branded and unbranded Contract manufacturing and supply of generics in the domestic pharmaceuticals Pharmaceutical formulations and medicines for market through our own di
Slide 10: Specialty Chemicals
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Specialty Chemicals Manufacturing and Supply of API, Intermediates and Specialty Chemicals having Wide Application in Our Clientele Paints, Coatings and Inks Fibres Fragrance and Perfumes Food Pharmaceuticals Pestic
Slide 11: Pharmaceutical Formulation & Institutional Supply
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Pharmaceutical Formulation & Institutional Supply The Products Manufactured have wide applications in Our Clientele Bronchial Diabetic / Cardiac Gynaecology Infertility Anti-Infectives Neuropsychiatric MD, Physician
Slide 12: Our Core Business Strategy
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Our Core Business Strategy Broaden and Deepen presence in existing product portfolio Increasing Operational Increase by targeting Efficiency unexplored markets 03 02 04 Strong Export Expand our scope by Division add
Slide 13: Company Structure
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Company Structure CMD HEMAL MEHTA JOINT MD SACHIN MEHTA COMPANY CEO CFO SECRETARY MANAGER MANAGER MANAGER API BULK PHARMA VIMAC ACCOUNT, LEGAL & PHARMA BANKING & DRUG FORMULATION TAX & SECRETARY COMPLIANCE FINANCE W
Slide 14: Our Recognition
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Our Recognition Received Brand brilliance in Pharma Sector Award From ASIAN–AFRICAN LEADERSHIP FORUM ON 23, MARCH 2019 Left to Right:- Dr. Neetu Singh, Director General of AACCI, Dr. G. D. Singh, Founder and Chairma
Slide 15: Board Of Directors
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Board Of Directors Mr. Hemal V. Mehta Mr. Sachin V. Mehta Mr. Chetan Kantilal Mehta Chairman and Managing Director Joint Managing Director Director With an experience of 15 years in Sourcing and Supply of Mr Sachin
Slide 16: Board Of Directors
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Board Of Directors Dr. Ujwala Vilas Salvi Mr. Sandeep Rameshchandra Mehta Mr. Hetang Shah Independent Director Independent Director-Non Executive Independent Director An Executive MBA in Healthcare from IIM Kolkata
Slide 17: Executive Management Team
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Executive Management Team Mr. Shekhar Bhuwania Mr. Indraraj Neogi Mr. Vinay Kumar Singh Chief Financial Officer India Head in Sales and Marketing Head of Pharma business in Manufacturing and Strategic Marketing Qual
Slide 18: Business Clientele
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Business Clientele 18 Investor Presentation
Slide 19: Investment Proposition
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Investment Proposition Established Belief in Cost plus Manufacturing and formula and after supply chain for sales services Chemical, Pharma and formulation Quality Manufacturing Experienced Management Facility with
Slide 20: Pharmaceutical Industry Overview
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Pharmaceutical Industry Overview 20
Slide 21: Indian Pharmaceutical Market
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Indian Pharmaceutical Market Segment Wise Moving Annual Turnover2 #1 #2 200 December 2017 (US$ billion) Largest provider of generic Largest share of pharma & Countries India exports Anti-Infectives 2.46 medicines bi
Slide 22: Outlook On Exports Of Indian Pharmaceutical
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Outlook On Exports Of Indian Pharmaceutical o India is the world’s largest provider of generic medicines; the country’s generic drugs Major Export Destinations in India’s Pharma Export in FY18 (%) account for 20 per
Slide 23: Indian Pharmaceutical Sector – Segmental Views
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Indian Pharmaceutical Sector – Segmental Views Active Pharmaceutical Ingredients (APIs) Contract Research and Manufacturing Services (CRAMS) Domestic API consumption is expected to reach US$ 18.8 billion by FY22. Fr
Slide 24: Growth Drivers Of Indian Pharmaceutical Sector
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Growth Drivers Of Indian Pharmaceutical Sector Supply-Side Drivers Demand-Side Drivers o Cost advantage o Increasing fatal diseases o Skilled manpower o Accessibility of drugs to greatly improve o India a major manu
Slide 25: Road Ahead
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Road Ahead 25
Slide 26: Future Roadmap
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Future Roadmap To Set up a dedicated State-of-the-Art Introduce Cardiac First Aid Kit, Heart Kit and New Manufacturing (Oral Solid Dosage) plant with a F&O Drug Delivery System (Mouth dissolving strips) for Research
Slide 27: Product Focus - Pharmaceuticals
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Product Focus - Pharmaceuticals JIVANKIT SETDOWN IREN RX HEART INFORT Q-10 General Tonic for Immunity Bowel Regulator Iron Deficiency - Anemia KIT 4 Infertility Cure Booster “JIVAN KIT” is India’s a First Unique Med
Slide 28: Product Focus - Pharmaceuticals
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Product Focus - Pharmaceuticals FIXPOLLEN-M RIPRO-L PULMORELIEF AB PULMORELIEF VXIME-500 TABLETS Respiratory Anti-Allergic Anti Ulcer Therapy & GI Respiratory Bronchodialator Anti bacterial Prokynetic Market for med
Slide 29: Product Focus - Pharmaceuticals
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Product Focus - Pharmaceuticals PATTA PAPPAYA HEART KIT LD METFOCAL CAPSUL NITROPURE MacPPI DSR In Dengue Patta Pappaya ensure It is the first medicine in India that A complete solution for osteoporosis. Common solu
Slide 30: Product Focus – Lifestyle Division (Love-Bird)
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Product Focus – Lifestyle Division (Love-Bird) Sudarshan’s “Lovebird” OTC division is about to launch more than 150 quality Luxury lifestyle products. In this division the Company has already launched 8 Products LOV
Slide 31: Product Focus – Lifestyle Division (Love-Bird)
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Product Focus – Lifestyle Division (Love-Bird) Sudarshan’s “Lovebird” OTC division is about to launch more than 150 quality Luxury lifestyle products. In this division the Company has already launched 8 Products “Lo
Slide 32: Product Focus – Specialty Chemicals
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Product Focus – Specialty Chemicals “Creative Chemistry is our core competency” is a punch line of Sudarshan Pharma. We are dealing with more than 2,00,000 Specialty Chemicals & intermediates for our elite customers
Slide 33: Oxystrong Sole Distributor
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Oxystrong Sole Distributor Benefits In 2018, Sudharshan pharma introduced OXYSTRONG, an oxygen and disinfectant o To reduce the cost on electricity consumption cleaner to the Indian market such as o Sludge formation
Slide 34: SPIL – Forward Integration
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights SPIL – Forward Integration 05 Branded Generics Finished Formulation and F&O 04 Research & Development API Manufacturing and 03 Import 02 Intermediates for API Chemical Raw Material for 01 Pharmaceuticals 34 Investor
Slide 35: Strong Financial Performance
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Strong Financial Performance 35
Slide 36: Strong Financial Performance
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Strong Financial Performance Rs. In Lacs Revenue from Operations EBITDA 13,809 517 CAGR - 53.89% CAGR – 8,815 140.35% 5,537 220 3,789 74 37 FY16 FY17 FY18 FY19 FY16 FY17 FY18 FY19 PBT PAT 327 235 CAGR – CAGR – 185.8
Slide 37: Strong Financial Performance
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Strong Financial Performance Working Capital Days Net Worth (in Rs. Lakhs) 1,874 52 53 43 854 13 321 165 FY16 FY17 FY18 FY19 FY16 FY17 FY18 FY19 ROE & ROCE (%) Debt to Equity(X) 56.1 7.69 24.41 21.64 18.97 11.79 8.7
Slide 38: Profit and Loss Statement
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Profit and Loss Statement Rs. In Lacs Particulars 2019 2018 2017 2016 Revenue I Revenue From Operation Sale of Products 13,913.02 8,814.51 5,537.21 3,789.02 II. Other Income - Commission and others 88.94 161.92 14.5
Slide 39: Balance Sheet
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Balance Sheet Rs. In Lacs Particulars FY19 FY18 FY17 FY16 Equity & Liabilities Share Capital 954.70 471.97 216.97 1.00 Share Application Money - - - - Reserve & Surplus 919.68 382.15 104.18 15.52 Total (A) 1,874.38
Slide 40: Financial Highlights
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Financial Highlights Rs. In Lacs Particulars FY19 FY18 FY17 FY16 Equity Share Capital 954.70 471.97 216.97 1.00 Reserves and Surplus 919.68 382.15 104.18 15.52 Net Worth 1,874.38 854.12 321.14 16.52 Sales 14,001.96
Slide 41: IPO Issue Highlights
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights IPO Issue Highlights 41
Slide 42: IPO Issue Information
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights IPO Issue Information Equity Shares to be Listed on NSE Emerge SME Equity Platform, Mumbai IPO Fixed price IPO Offer Price – Indicative Rs. 75 per equity share of Rs. 10 each (Rs. 65 share premium) Lot Size 1600 equ
Slide 43: Object of Issue
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Object of Issue The Net Proceeds from the Issue are proposed to be utilized by the Company for following objects: • To set up a dedicated manufacturing facility for Pharmaceutical Business • Distribution and Warehou
Slide 44: Deployment of Funds
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Deployment of Funds Particulars Amount ( In lacs) Land & Building & Infra at Wada for Pharma Unit 625 Machines, Equipment & Power, QC and R &D 625 Working Capital 525 Distribution and Warehousing & Corporate office
Slide 45: Conclusion
Corporate Identity Industry Overview Road Ahead Financial Performance IPO Highlights Conclusion India has evolved as "Pharmacy of the World" and Pharma is a sector which is relatively immune to domestic macro and associated volatility. With experienced management, professional approach and an impres
Slide 46: THANK YOU
Corporate Video THANK YOU Head Office: 301, Sudarshan House, Aura Biplex Landmark Kalyan Jewellers, S V Road, Borivali(West). Mumbai – 400 092. Telephone: +91 22 4222 1100 https://www.youtube.com/channel/UCmgz6ji_- info@sudarshanpharma.com http://www.sudarshanpharma.com 1WLS4ZrlHYGj3g/videos?view_as